Program
telisotuzumab adizutecan
Also written as “Telisotuzumab Adizutecan”, “RC148 plus Telisotuzumab adizutecan” and “ABBV-400”.
In AbbVie’s pipeline, c-Met
. Its studies are mostly in Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Neoplasms · Squamous Cell Carcinoma of Head and Neck · Carcinoma, Hepatocellular, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVieits history only | 1717 open or running | phase 3since May 27, 2025 | Aug 30, 2021 | Dec 2026phase 2 · NCT06107413 |
| RemeGenits history only | 11 open or running | phase 2since Oct 12, 2026 | Oct 12, 2026 | Jul 2028phase 2 · NCT07895355 |
- Named in AbbVie’s own pipeline as
Temab-A (ABBV-400)
, phase 3, as of Jul 30, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 5 earlier studies, Aug 30, 2021 to Sep 25, 2024.
- Feb 29, 2024Named telisotuzumab adizutecanINNProposed as its International Nonproprietary Name in WHO's List 130 · before, ABBV-400
- Oct 3, 2024Phase 2 study in Adenocarcinoma Of EsophagusAbbVie · NCT06628310 · 185 enrolled · United States, Belgium, Canada and more
- Jan 9, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungAbbVie · NCT06772623 · 252 planned · United States, Argentina, Australia and more
- Feb 6, 2025Phase 2 study in Colorectal NeoplasmsAbbVie · NCT06820463 · 390 planned · United States, Australia, Austria and more
- May 27, 2025Phase 3 study in NeoplasmsAbbVie · NCT07005102 · 854 planned · United States, Australia, Belgium and more
- Jun 10, 2025Phase 2 study in Colorectal NeoplasmsAbbVie · NCT07023289 · 140 planned · United States, Belgium, Denmark and more
- Aug 28, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungAbbVie · NCT07155187 · 490 planned · United States, Australia, Austria and more
- Sep 22, 2025Phase 2 study in Solid Tumors Harboring MET AmplificationAbbVie · NCT07196644 · 100 planned · United States, Israel, Japan and more
- Mar 13, 2026Phase 3 study in Metastatic Pancreatic Ductal AdenocarcinomaAbbVie · NCT07490301 · 900 planned · United States, Australia, Israel and more
- Apr 7, 2026Phase 3 study in Colorectal NeoplasmsAbbVie · NCT07525206 · 990 planned · United States, Belgium, China and more
- Jul 30, 2026Phase 2 study in Squamous Cell Carcinoma of Head and NeckAbbVie · NCT07744126 · 150 planned · United States, Japan, Taiwan
- Aug 13, 2026Phase 2 study in NeoplasmsAbbVie · NCT07769502 · 168 planned · United States, Israel, Japan and more
- Sep 10, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungAbbVie · NCT07821684 · 660 planned
- Oct 5, 2026Primary completion moved from 2031-12 to 2036-11Date moved laterphase 3 · +59 months · NCT07005102
- Oct 12, 2026RemeGen’s first study: phase 2 study in Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line TherapyNew to RemeGenRemeGen · NCT07895355 · 412 planned · China
Ahead
- Dec 2026Primary completion: phase 2 study in NeoplasmsAbbVie · NCT06107413
- Aug 2027Primary completion: phase 2 study in Colorectal NeoplasmsAbbVie · NCT06614192
- Sep 2027Primary completion: phase 1 study in Carcinoma, HepatocellularAbbVie · NCT06084481
- Nov 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungAbbVie · NCT06772623
TargetBeta
“c-Met”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the tumor-associated antigen (TAA) proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) ”NCIt, by rule
Other programs on MET
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cabozantinibrule | Exelixis | phase 4 | 36 |
| Crizotinibrule | Pfizer | phase 4 | 31 |
| zanzalintinibrule | Exelixis | phase 3 | 17 |
| amivantamabrule | Johnson & Johnson | phase 3 | 16 |
| vebreltinibrule | beijing-pearl-biotechnology-limited-liability-company | phase 3 | 9 |
| glumetinibrule | Haihe Biopharma | phase 3 | 8 |
| vilzemetkib | Sino Biopharmaceutical | phase 3 | 8 |
| dalmelitinib | Hansoh Pharmaceutical Group | phase 3 | 7 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| HS-20117 | Hansoh Pharmaceutical Group | phase 3 | 3 |
| SHR-1826 | Jiangsu HengRui Medicine | phase 2 | 7 |
| pamvatamigrule | Betta Pharmaceuticals | phase 2 | 5 |
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07895355Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy · China | 2 | Not yet recruiting | RemeGen | Jul 2028 | 412 |
| NCT07821684Carcinoma, Non-Small-Cell Lung | 3 | Not yet recruiting | AbbVie | Mar 2030 | 660 |
| NCT07769502Neoplasms · United States, Israel, Japan and more | 2 | Recruiting | AbbVie | Sep 2028 | 168 |
| NCT07744126Squamous Cell Carcinoma of Head and Neck · United States, Japan, Taiwan | 2 | Recruiting | AbbVie | Oct 2029 | 150 |
| NCT07525206Colorectal Neoplasms · United States, Belgium, China and more | 3 | Recruiting | AbbVie | May 2029 | 990 |
| NCT07490301Metastatic Pancreatic Ductal Adenocarcinoma · United States, Australia, Israel and more | 3 | Recruiting | AbbVie | Jun 2031 | 900 |
| NCT07196644Solid Tumors Harboring MET Amplification · United States, Israel, Japan and more | 2 | Recruiting | AbbVie | Dec 2030 | 100 |
| NCT07155187Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more | 3 | Recruiting | AbbVie | Sep 2030 | 490 |
| NCT07023289Colorectal Neoplasms · United States, Belgium, Denmark and more | 2 | Recruiting | AbbVie | Nov 2029 | 140 |
| NCT07005102Neoplasms · United States, Australia, Belgium and more | 3 | Recruiting | AbbVie | Nov 2036 | 854 |
| NCT06820463Colorectal Neoplasms · United States, Australia, Austria and more | 2 | Recruiting | AbbVie | Mar 2028 | 390 |
| NCT06772623Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 2 | Recruiting | AbbVie | Nov 2027 | 252 |
| NCT06628310Adenocarcinoma Of Esophagus · United States, Belgium, Canada and more | 2 | Active, not recruiting | AbbVie | Oct 2030 | 185 |
| NCT06614192Colorectal Neoplasms · United States, Australia, Israel and more | 2 | Active, not recruiting | AbbVie | Aug 2027 | 74 |
| NCT06464692Colorectal Neoplasms · China | 1 | Active, not recruiting | AbbVie | Dec 2027 | 31 |
| NCT06107413Neoplasms · United States, Belgium, Germany and more | 2 | Active, not recruiting | AbbVie | Dec 2026 | 280 |
| NCT06084481Carcinoma, Hepatocellular · United States, Australia, Israel and more | 1 | Recruiting | AbbVie | Sep 2027 | 325 |
| NCT05029882Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more | 1 | Active, not recruiting | AbbVie | Nov 2027 | 520 |
How it is read
Names in the registry
- “Telisotuzumab Adizutecan”, 12 entries
- “RC148 plus Telisotuzumab adizutecan”, 4 entries
- “ABBV-400”, 3 entries
- “Telisotuzumab adizutecan”, 2 entries
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 6 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Neoplasms, 3 studies
- Squamous Cell Carcinoma of Head and Neck, 1 study
- Carcinoma, Hepatocellular, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.